Pathstone Holdings
CRNX icon

Pathstone Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pathstone Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$782K Sell
20,888
-2,340
-10% -$87K ﹤0.01% 1640
2026
Q1 		$844K Sell
23,228
-1,834
-7% -$81.9K ﹤0.01% 1489
2025
Q4 		$1.17M Buy
25,062
+2,186
+10% +$97.3K ﹤0.01% 1316
2025
Q3 		$953K Sell
22,876
-2,397
-9% -$76.6K ﹤0.01% 1454
2025
Q2 		$727K Sell
25,273
-3,042
-11% -$93.9K ﹤0.01% 1546
2025
Q1 		$950K Buy
28,315
+7,887
+39% +$295K ﹤0.01% 1413
2024
Q4 		$1.04M Buy
+20,428
New +$1.14M ﹤0.01% 1348

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's CRNX Position: Q2 2026 in Review

Pathstone Holdings reduced its Crinetics Pharmaceuticals (CRNX) stake by 10% in Q2 2026, selling an estimated $87K and leaving 20,888 shares worth $782K. The position accounts for ﹤0.01% of the portfolio, ranked #1640.

Pathstone Holdings first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.17M in Q4 2025. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Pathstone Holdings held 20,888 shares of Crinetics Pharmaceuticals worth $782K as of Q2 2026.
  • Pathstone Holdings sold 2,340 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $87K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1640 holding.
  • Pathstone Holdings first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Pathstone Holdings's Crinetics Pharmaceuticals position peaked at $1.17M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.